LICENSE agreementLicense Agreement • March 27th, 2017 • Albireo Pharma, Inc. • Pharmaceutical preparations • England
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
FIRST AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • March 27th, 2017 • Albireo Pharma, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT (the “First Amendment”) to the License Agreement, dated as of April 2, 2012 (the “Agreement”), by and between Albireo AB (“Albireo”) and Ajinomoto Pharmaceuticals Co, Ltd. (“Ajinomoto”) is entered into on January 30, 2015.
SECOND AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • March 27th, 2017 • Albireo Pharma, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT (the “Second Amendment”) to the License Agreement, dated as of April 2, 2012 (the “Original License Agreement”), as amended on January 30, 2015, (the “Agreement”), by and between Elobix AB (“Elobix”) and EA Pharma Co., Ltd. (formerly known as Ajinomoto Pharmaceuticals Co., Ltd., “EA”) is entered into on April 6, 2016. Elobix and EA may each be referred to herein individually as a “Party” and collectively as the “Parties.”
